Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free MRV Stock Alerts

Nuvo Pharmaceuticals (MRV) Competitors

C$38.23 +1.48 (+4.03%)
As of 09/11/2026 03:59 PM Eastern
Compare

MRV vs. APH, VRX, APHA, BHC, and MJN

Should you buy Nuvo Pharmaceuticals stock or one of its competitors? Nuvo Pharmaceuticals's main competitors and comparable companies include Aphria (APH), Valeant Pharmaceuticals International (VRX), Aphria (APHA), Bausch Health Companies (BHC), and Cronos Group (MJN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Nuvo Pharmaceuticals compare to Aphria?

Nuvo Pharmaceuticals (TSE:MRV) and Aphria (TSE:APH) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Aphria Neutral

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Aphria N/A N/A N/A

Nuvo Pharmaceuticals has a beta of 0.917796, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Aphria has a beta of 3.455044, suggesting that its stock price is 246% more volatile than the broader market.

Aphria has higher revenue and earnings than Nuvo Pharmaceuticals. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B3.94C$15.17MC$2.9113.14
AphriaC$29.01B9.88C$4.93BC$0.4358.14

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Aphria shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nuvo Pharmaceuticals beats Aphria on 6 of the 11 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Nuvo Pharmaceuticals (TSE:MRV) and Valeant Pharmaceuticals International (TSE:VRX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Valeant Pharmaceuticals International'saverage media sentiment score.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Valeant Pharmaceuticals International Neutral

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Valeant Pharmaceuticals International's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Valeant Pharmaceuticals International's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Valeant Pharmaceuticals International N/A N/A N/A

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B3.94C$15.17MC$2.9113.14
Valeant Pharmaceuticals InternationalN/AN/AN/AN/AN/A

Summary

Nuvo Pharmaceuticals beats Valeant Pharmaceuticals International on 6 of the 6 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Aphria?

Aphria (TSE:APHA) and Nuvo Pharmaceuticals (TSE:MRV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aphria's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Aphria Neutral
Nuvo Pharmaceuticals Neutral

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AphriaC$611.06M0.00-C$637.39M-C$2.01N/A
Nuvo PharmaceuticalsC$8.72B3.94C$15.17MC$2.9113.14

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company Net Margins Return on Equity Return on Assets
AphriaN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Summary

Nuvo Pharmaceuticals beats Aphria on 9 of the 9 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Nuvo Pharmaceuticals (TSE:MRV) and Bausch Health Companies (TSE:BHC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvo Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Bausch Health Companies' net margin of -12.02%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Bausch Health Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Bausch Health Companies -12.02%87.57%4.16%

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Bausch Health Companies shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nuvo Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B3.94C$15.17MC$2.9113.14
Bausch Health CompaniesC$10.85B0.28-C$125.65M-C$2.94N/A

Nuvo Pharmaceuticals has a beta of 0.917796, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.707626, meaning that its stock price is 29% less volatile than the broader market.

In the previous week, Bausch Health Companies had 1 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 1 mentions for Bausch Health Companies and 0 mentions for Nuvo Pharmaceuticals. Bausch Health Companies' average media sentiment score of 0.21 beat Nuvo Pharmaceuticals' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the news media.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Bausch Health Companies Neutral

Summary

Nuvo Pharmaceuticals beats Bausch Health Companies on 8 of the 14 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Cronos Group?

Cronos Group (CVE:MJN) and Nuvo Pharmaceuticals (TSE:MRV) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Nuvo Pharmaceuticals Neutral

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupN/AN/AN/AN/AN/A
Nuvo PharmaceuticalsC$8.72B3.94C$15.17MC$2.9113.14

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Cronos Group's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos GroupN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Summary

Nuvo Pharmaceuticals beats Cronos Group on 6 of the 6 factors compared between the two stocks.

Get Nuvo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRV vs. The Competition

Export
MetricNuvo PharmaceuticalsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$34.31BC$12.41BC$7.16BC$12.71B
Dividend Yield0.03%2.64%2.57%6.28%
P/E Ratio13.14799.75274.9440.10
Price / Sales3.94756.96633.809.50
Price / Cash0.2314.8628.4282.29
Price / Book50.9710.3910.334.67
Net IncomeC$15.17MC$2.85BC$3.50BC$299.09M
7 Day Performance5.61%-3.61%-3.32%-1.33%
1 Month Performance5.84%0.72%-0.53%-1.21%
1 Year PerformanceN/A3.61%23.51%23.50%

Nuvo Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRV
Nuvo Pharmaceuticals
N/AC$38.23
+4.0%		N/AN/AC$34.31BC$8.72B13.147,480
APH
Aphria
N/AC$24.37
+2.3%		N/AN/AC$30.05BC$29.01B6.0980,000
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AC$10.76BN/AN/AN/A
APHA
Aphria
N/AN/AN/AN/AC$5.24BC$611.06MN/A1,200
BHC
Bausch Health Companies
0.4791 of 5 stars		C$9.32
-1.5%		N/A-19.5%C$3.49BC$10.85BN/A19,900

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MRV) was last updated on 9/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel